Last updated
BPC-157 and GHK-Cu are often grouped under “recovery” or “regeneration,” but they are quite different molecules doing different jobs in different tissue — a systemic injury-repair peptide versus a copper-carrying skin and matrix signal. Grouping them by outcome hides how little they share by mechanism.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | BPC-157 | GHK-Cu |
|---|---|---|
| Structure | 15-aa pentadecapeptide (gastric-derived) | Copper-bound tripeptide (Gly-His-Lys) |
| Primary mechanism | VEGFR2–Akt–eNOS angiogenesis + nitric-oxide signaling | Copper delivery + ECM-remodeling gene modulation |
| Target tissue | Tendon, ligament, muscle, GI tract (systemic) | Skin, extracellular matrix, hair follicle |
| Typical route (research) | Injected / oral (systemic) | Topical / local (also injectable) |
| Best-studied for | Musculoskeletal and gut repair | Collagen / elastin synthesis, wound healing, skin aging |
| Evidence base | Preclinical (largely rodent, one main group); no controlled human trials | Extensive dermatologic / cosmetic literature, incl. human topical data |
| Status | Research compound — not FDA-approved | Cosmetic ingredient (Copper Tripeptide-1) / research |
| Molecular weight | 1419.5 Da | 401.9 Da |
BPC-157 is a 15-residue peptide derived from a protective protein in gastric juice, studied as a systemic pro-angiogenic and cytoprotective agent — its repair effects are attributed largely to the VEGFR2–Akt–eNOS pathway and nitric-oxide signaling, with the most-replicated results in tendon, ligament, and gastrointestinal models. The honest caveat is evidence quality: essentially all of it is preclinical, much from a single research group, with no controlled human trials.
GHK-Cu is a different kind of molecule and a different kind of literature. It is the copper complex of the tripeptide glycyl-histidyl-lysine, first isolated from human plasma in 1973, and it works by delivering copper and shifting the expression of extracellular-matrix and antioxidant genes. Its evidence is concentrated in dermatology and cosmetics — including human topical data — where it is a reference “copper peptide” (INCI Copper Tripeptide-1) for collagen support, wound healing, and skin aging. So the two overlap only at the vaguest level (“repair”): one is a systemic injury peptide with thin human data, the other a topical skin/matrix signal with a deeper cosmetic record.
These are complementary tools for different questions, not substitutes. BPC-157 is studied for systemic tissue and gut repair through angiogenesis and nitric-oxide signaling, with a preclinical-only evidence base. GHK-Cu is the reference copper peptide for skin and extracellular-matrix remodeling, with a much deeper dermatologic and cosmetic literature. Neither is an FDA-approved drug — GHK-Cu is a cosmetic ingredient, BPC-157 a research compound — and grouping them as one “recovery” category obscures how differently they act. This page is a research and educational reference.
BPC-157 is a 15-amino-acid peptide studied for systemic tissue repair — tendon, ligament, and gut — through angiogenesis (the VEGFR2–Akt–eNOS pathway) and nitric-oxide signaling. GHK-Cu is a copper-bound tripeptide studied for skin and extracellular-matrix remodeling (collagen, elastin) and wound healing. Different structures, mechanisms, and target tissue.
Because they act on different tissue by different mechanisms, they are sometimes discussed together in “recovery” contexts, but there is no controlled human data on the combination. This page is a research reference, not a protocol.
They have different kinds of evidence. GHK-Cu has an extensive dermatologic and cosmetic literature, including human topical studies. BPC-157’s evidence is almost entirely preclinical (mostly rodent, much from a single group), with no controlled human trials. Neither is an approved drug.
No. BPC-157 is a research compound and is not FDA-approved for any use. GHK-Cu is used as a cosmetic ingredient (Copper Tripeptide-1), not an approved drug. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between BPC-157 and GHK-Cu — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.